Skip to main content

Advertisement

SpringerLink
Log in

Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

This study aimed to investigate the association of epidermal growth factor receptor (EGFR) mutation status with treatment outcome for patients with stage 3 non-small cell lung cancer (NSCLC) who had undergone a complete (R0) resection.

Methods

The study identified 3445 NSCLC patients tested for EGFR mutations between September 2001 and December 2011 at the Sun Yat-Sen University Cancer Center. Of these patients, 224 were stage 3 patients who had undergone R0 resections.

Results

These 224 R0-resected, pathologic stage 3A and 3B patients included 150 patients with wild-type EGFR and 74 patients with EGFR mutations. During a median follow-up period of 42 months (range, 4–133 months), pathologic stage was shown to be the only prognostic factor. The 3-year overall survival (OS) rates did not differ significantly from the OS rates for the wild-type and mutant EGFR groups (62.0 vs 67.2 %; p = 0.789). Multivariate analyses indicated that the patients in the mutant EGFR group with EGFR exon 19 mutations had a better OS rate (73.0 vs 61.1 %; p = 0.026).

Conclusions

Cancer stage remained the significant prognostic factor in R0-resected stage 3 NSCLC patients. The presence of an EGFR mutation is more likely to be a predictive marker for the response to treatment with tyrosine kinase inhibitors. In the EGFR mutant group, the patients with an exon 19 mutation had better 3-year OS rates. These findings might be considered in future study designs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004;4:351–60.

    Google Scholar 

  2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9. doi:10.1200/JCO.2007.13.9030.

    Article  PubMed  Google Scholar 

  3. Strauss GM, Herndon JN, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol. 2008;31:5043–51.

    Article  Google Scholar 

  4. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin Vs: observation in resected non-small cell lung cancer. N Engl J Med. 2005;25:2589–97.

    Article  Google Scholar 

  5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;9:719–27.

    Article  Google Scholar 

  6. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;1: 260–71.

    Article  Google Scholar 

  7. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT Gefitinib trials. J Clin Oncol. 2005;31: 8081–92.

    Article  Google Scholar 

  8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;25: 5900–9.

    Article  Google Scholar 

  9. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;3:239–46.

    Article  Google Scholar 

  10. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase 3, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;21:2866–74.

    Article  Google Scholar 

  11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;8:735–42.

    Article  Google Scholar 

  12. Zhang Z, Wang T, Zhang J, et al. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. Plos One. 2014;8:e106053.

    Article  Google Scholar 

  13. Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011;3:569–75.

    Article  Google Scholar 

  14. Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;5:1336–43.

    Google Scholar 

  15. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;9:845–53.

    Article  Google Scholar 

  16. Kato M, Onishi H, Matsumoto K, et al. Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small cell lung cancer. Anticancer Res. 2012;11:5099–104.

    Google Scholar 

  17. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(Suppl 5):e314S–40S.

    Article  CAS  PubMed  Google Scholar 

  18. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2010;1:291–303.

    Article  Google Scholar 

  19. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;11:2493–501.

    Article  Google Scholar 

  20. D’Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;12:1815–22.

    Article  Google Scholar 

  21. Kim YT, Seong YW, Jung YJ, et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small cell lung cancer. J Thorac Oncol. 2013;2:171–8.

    Article  Google Scholar 

  22. Sun HB, Ou W, Li Y, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small cell lung cancer. Clin Lung Cancer. 2013;4:376–82.

    Article  Google Scholar 

  23. Luo YH, Chen YM. Influence of chemotherapy on EGFR mutation status. Transl Lung Cancer Res. 2013;6:442–4.

    Google Scholar 

Download references

Disclosure

There are no conflicts of interest.

Author information

Author notes

    Authors and Affiliations

    1. State Key Laboratory of Oncology in South China, Guangzhou, People’s Republic of China

      Song Ran Liu MD, Bo Qiu MD, PhD, Hong Yang MD, PhD, Ying Liang MD, PhD, Fang Wang MD, PhD, Shi Liang Liu MD, Zhao Lin Chen MS, Li Zhang MD, PhD, Meng Zhong Liu MD, Si Yu Wang MD, Lan Feng Lin MS & Hui Liu MD

    2. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China

      Song Ran Liu MD, Bo Qiu MD, PhD, Shi Liang Liu MD, Zhao Lin Chen MS, Meng Zhong Liu MD, Lan Feng Lin MS & Hui Liu MD

    3. Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

      Hong Yang MD, PhD & Si Yu Wang MD

    4. Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

      Ying Liang MD, PhD & Li Zhang MD, PhD

    5. Molecular Diagnosis, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

      Fang Wang MD, PhD

    6. Guangdong Association Study of Thoracic Oncology, Guangzhou, People’s Republic of China

      Song Ran Liu MD, Bo Qiu MD, PhD, Hong Yang MD, PhD, Ying Liang MD, PhD, Fang Wang MD, PhD, Shi Liang Liu MD, Zhao Lin Chen MS, Li Zhang MD, PhD, Meng Zhong Liu MD, Si Yu Wang MD, Lan Feng Lin MS & Hui Liu MD

    Authors
    1. Song Ran Liu MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Bo Qiu MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Hong Yang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Ying Liang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Fang Wang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Shi Liang Liu MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Zhao Lin Chen MS
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Li Zhang MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Meng Zhong Liu MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Si Yu Wang MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Lan Feng Lin MS
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Hui Liu MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Hui Liu MD.

    Additional information

    Song Ran Liu, Bo Qiu and Hong Yang have contributed equally to this article.

    Lan Feng Lin is the co-corresponding author of this article.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Liu, S.R., Qiu, B., Yang, H. et al. Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer. Ann Surg Oncol 23, 2115–2122 (2016). https://doi.org/10.1245/s10434-015-5076-0

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-015-5076-0

    Keywords

    Search

    Navigation